Dr. Kuo on PSMA-PET imaging biomarker research


Phillip Kuo, MD, PhD, Departments of Medical Imaging, Medicine, and Biomedical Engineering, University of Arizona, discusses the abstract, “[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy,” which was presented at the 2022 ASCO Annual Meeting.

The post-hoc exploratory analysis specifically showed that a higher whole-body SUVmean was strongly associated with improved long-term clinical outcomes among men in the VISION trial with PSMA-positive mCRPC on 68Ga-PSMA-11 PET/CT treated with 177Lu-PSMA-617.

Recent Videos
David I. Lee, MD, FACS, answers a question during a video interview
Todd M. Morgan, MD, answers a question during a Zoom video interview
Man talking with doctor | Image Credit: © rocketclips - stock.adobe.com
Prostate cancer cell division | Image Credit: © PRB ARTS - stock.adobe.com
Group of doctors reading a document | Image Credit: © Flamingo Images - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.